David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition

David Sinclair's XPrize entry to test oral reprogramming drugs signals a pivotal shift toward commercializing anti-aging therapies. If successful, this could unlock a massive longevity economy by 2026, reshaping healthcare, insurance, and workforce productivity. AI-driven biomarker analysis will be critical for measuring "rejuvenation," accelerating regulatory pathways and spawning new markets for age-reversal interventions.